Menu Close

Trending

Vir awarded $1 billion multi-year BARDA influenza contract
GSK’s Jemperli/TIM-3 immuno-oncology combo moves to ph3
Digital health financing drops again, but don’t worry yet
Sanofi wagers $400m on miRecule muscular dystrophy therapy
Cutting the combination therapy access issue down to size

Featured content right column

Featured content right column

How to improve payer engagement with tailored value communication

Deep Dive/ Featured content right column/ Market Access/ Views & Analysis/ Views and analysis

How to improve payer engagement with tailored value communication

, , , , 0 Comment

Pharmaceutical drug success rests on being able to achieve market access. Brands are facing increasing pressure to demonstrate

X
How to improve payer engagement with tailored value communication
https://pharmaphorum.com/views-analysis-market-access/how-to-improve-payer-engagement-with-tailored-value-communication/
How will NICE fare in a post-Brexit world?

Deep Dive/ Featured content right column/ Market Access/ Views & Analysis/ Views and analysis

How will NICE fare in a post-Brexit world?

, , , , , , 0 Comment

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that

X
How will NICE fare in a post-Brexit world?
https://pharmaphorum.com/views-analysis-market-access/how-will-nice-fare-in-a-post-brexit-world/

Featured content right column/ Partner content/ Press releases

Ashfield Advisory launches its Advisory Ecosystem in response to market demand

, , , , 0 Comment

Ashfield Advisory launches its Advisory Ecosystem

X
Ashfield Advisory launches its Advisory Ecosystem in response to market demand
https://pharmaphorum.com/partner-content/ashfield-advisory-launches-its-advisory-ecosystem-in-response-to-market-demand/

Login

CONTINUE TO SITE >
X
Close in 10 seconds